The facility will be located at Ongkharak Nuclear Research Centre in Nakhon Nayok. With an area of more than 5400 m2, the new complex will accommodate a cyclotron and several laboratories for the production of radiopharmaceuticals for nuclear medicine and other purposes, as well as serve as a platform for R&D activities in the field of radiation technologies and innovations.
Currently all the isotopes for SPECT in Thailand are imported, with some PET isotopes produced in hospitals locally in amounts that cannot satisfy the demand. Thus, the new cyclotron supplied by ROSATOM will allow Thailand to produce its own isotopes and will also drive the R&D activities in nuclear medicine, as well as in application of nuclear technologies in the different areas of industry.
“We are happy to be a part of the project that will help to save lives and to boost innovations in Thailand. ROSATOM has decades of experience in designing and manufacturing nuclear healthcare and R&D solutions. There are 14 radionuclide production facilities operating in Russia”, said Alexander Merten, President of RUSATOM International Network.
RUSATOM International Network (a subsidiary of ROSATOM) operating global network of representative offices for ROSATOM, with its office for Southeast Asia countries operating out of Singapore facilitated the deal.
The core of the complex will be a MCC-30/15 cyclotron of 30 MeV proton energy, supplied by ROSATOM. It will be utilized also to produce isotopes for PET and SPECT diagnostics. These isotopes allow determining the stage of oncological, cardiac, and neurological diseases accurately, and in many cases may be almost the only way to prescribe appropriate treatment.
ROSATOM is the Russian Federation national nuclear corporation that comprises more than 350 nuclear industry companies and institutions. With over 70 years of experience in the field of nuclear technology, ROSATOM works on a global scale to provide comprehensive nuclear services that range from uranium enrichment to nuclear power plant construction as one of the global leaders in nuclear industry. ROSATOM has a strong focus on applied research and innovations and invests 4.5% of its annual revenues into R&D projects. The technologies of the Russian nuclear industry have been used to build over 120 research reactors globally.
RUSATOM International Network is an industry complex under the governance of ROSATOM with a mission to develop and manage a network of ROSATOM regional centres. The company is comprised of 11 regional centres. The main tasks of the company and its regional centres are to seek new opportunities to expand business, promote Russian nuclear companies’ products and services globally.
Through its subsidiary RUSATOM Healthcare, ROSATOM provides the full range of services in nuclear medicine, from facilities construction and operation to the supply of isotopes worldwide. The company implements projects in two areas: nuclear medicine and innovative product processing technologies.
Kinetics Corporation Ltd. was founded in 1986 with the aim to be the one stop complete solution provider in the field of engineering and scientific equipment. Kinetics, with more than 30 years of experiences in the market, is trusted by customers in both public and private sectors. Entering into its fourth decade, Kinetics continues to strive for the best in the future to come.